Fulgent Genetics (FLGT) Current Assets (2015 - 2026)

Fulgent Genetics has reported Current Assets for 12 years, with the latest figure at $454.8 million in Q2 2026.

• Quarterly Current Assets rose 6.07% year-over-year to $454.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $454.8 million (up 6.07% YoY) and the FY2025 annual result came in at $550.5 million, up 55.69% from the prior year.
• Current Assets eased to $454.8 million in Q2 2026 per FLGT's latest filing, from $479.0 million in the prior quarter.
• Over five years, Current Assets peaked at $765.3 million in Q1 2022 and troughed at $326.5 million in Q3 2024.
• A 5-year average of $513.0 million and a median of $507.6 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets sank 40.61% in 2024, then surged 55.69% in 2025.
• Over 5 years, Current Assets stood at $627.9 million in 2022, then slipped by 19.12% to $507.8 million in 2023, then tumbled by 30.38% to $353.6 million in 2024, then jumped by 55.69% to $550.5 million in 2025, then declined by 17.39% to $454.8 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $454.8 million, $479.0 million, and $550.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.